IQV vs. ICLR, MEDP, CRL, INCY, TAK, MRNA, CNC, IDXX, ALC, and HUM
Should you be buying IQVIA stock or one of its competitors? The main competitors of IQVIA include ICON Public (ICLR), Medpace (MEDP), Charles River Laboratories International (CRL), Incyte (INCY), Takeda Pharmaceutical (TAK), Moderna (MRNA), Centene (CNC), IDEXX Laboratories (IDXX), Alcon (ALC), and Humana (HUM). These companies are all part of the "medical" sector.
IQVIA (NYSE:IQV) and ICON Public (NASDAQ:ICLR) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, community ranking, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.
89.6% of IQVIA shares are owned by institutional investors. Comparatively, 95.6% of ICON Public shares are owned by institutional investors. 1.6% of IQVIA shares are owned by insiders. Comparatively, 44.0% of ICON Public shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
IQVIA has higher revenue and earnings than ICON Public. IQVIA is trading at a lower price-to-earnings ratio than ICON Public, indicating that it is currently the more affordable of the two stocks.
In the previous week, ICON Public had 4 more articles in the media than IQVIA. MarketBeat recorded 20 mentions for ICON Public and 16 mentions for IQVIA. IQVIA's average media sentiment score of 0.86 beat ICON Public's score of 0.42 indicating that IQVIA is being referred to more favorably in the media.
IQVIA received 38 more outperform votes than ICON Public when rated by MarketBeat users. Likewise, 68.03% of users gave IQVIA an outperform vote while only 64.99% of users gave ICON Public an outperform vote.
IQVIA has a net margin of 9.06% compared to ICON Public's net margin of 8.30%. IQVIA's return on equity of 29.32% beat ICON Public's return on equity.
IQVIA presently has a consensus price target of $256.80, indicating a potential upside of 9.05%. ICON Public has a consensus price target of $327.50, indicating a potential upside of 7.68%. Given IQVIA's higher probable upside, equities analysts plainly believe IQVIA is more favorable than ICON Public.
IQVIA has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, ICON Public has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.
Summary
IQVIA beats ICON Public on 11 of the 18 factors compared between the two stocks.
Get IQVIA News Delivered to You Automatically
Sign up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IQV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
